Search This Blog

Thursday, July 30, 2020

Opko Health Q2 top line up 33% on surge in reference lab unit

OPKO Health (NASDAQ:OPK) Q2 results:
Revenues: $301.2M (+33.0%); reference lab services: $251.0M (+40.6%); product sales: $29.3M (+2.1%).
Net income: $33.7M (+156.4%); EPS: $0.05 (+150.0%).
BioReference Labs unit processed ~2.2M COVID-19 molecular tests during the quarter.

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)